Mimedx agreed to buy Sanara Medtech for an enterprise value of about $350 million, aiming to move beyond its wound-care-heavy profile as reimbursement pressures hit skin substitute sales. In the most recent quarter cited with the deal, Mimedx reported a sharp decline in its wound segment and a broader top-line drop, setting up the acquisition as a strategic repositioning. The transaction is expected to increase Mimedx’s exposure to the surgical market while reducing the relative importance of wound care in its portfolio.